5 Dementia Medications that are Approved or in Clinical Trials

3. Aduhelm

Aduhelm is the brand name of Aducanumab is one of the dementia medications that are approved or in trial, specifically in the treatment of Alzheimer disease. Even though in 2022, Biogen Inc. (NASDAQ:BIIB), the manufacturer of Aduhelm, withdrew its application to the European Medicines Agency, citing the belief that the data provided so far would not enable a positive opinion on marketing the drug. However, clinical trials are still continuing and there is expected to the patients on clinical trial.